ReviewCurrent oncology reports2009
Molecular profiling in glioblastoma: prelude to personalized treatment.
Review in Current oncology reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Glioma malignancy is linked to interdependent and inverse AMOG and L1 adhesion molecule expression.BMC cancer · 2019Article
- A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.Stem cells (Dayton, Ohio) · 2014Article
- Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion.Neuro-oncology · 2012Article
- Integration and analysis of genome-scale data from gliomas.Nature reviews. Neurology · 2011Review
- Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.Journal of neuro-oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this review is to provide an up-to-date summary of the current knowledge and understanding of the molecular alterations and pathways relevant to the clinical outcome of glioblastoma patients and their potential use in designing personalized treatment for these patients. This article also discusses the potential of molecular profiling as a diagnostic modality, possible therapeutic implications of MGMT promoter methylation, the targeted inhibition of angiogenesis, and assessment of the tumor's molecular background with respect to PI3K/AKT pathway activation and associated molecules (EGFR, EGFRvIII, PTEN).
Indexed as
Identifiers
19080742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.